ARA-290 (Cibinetide) vs BPC-157 — Peptide Comparison

ARA-290 (Cibinetide) vs BPC-157 — Peptide Comparison ARA-290 (Cibinetide) vs BPC-157 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range ARA-290 (Cibinetide) 0.16 mg–0.8 mg mg BPC-157 250–500 mcg Frequency Once daily Administration Subcutaneous injection Cycle Length Ongoing/indefinite 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Strong preclinical (extensive animal studies) Efficacy Nerve Regeneration Pain Management Tissue Protection Primary Benefit Secondary Benefit Additional Benefit Technical Data Molecular Formula C51H84N16O21 Molecular Weight 1257.31 g/mol Half-Life Approximately 1-2 hours in circulation, but cellular effects last much longer Bioavailability Subcutaneous: ~100% (complete absorption); Intravenous: Immediate CAS Number 1208243-50-8 C62H98N16O22 1419.53 g/mol 4-6 hours ~100% (subcutaneous) 137525-51-0 Protocols starting 1 mg 28 days Lowest dose tested in the phase 2 sarcoidosis nerve study. A good starting point while watching how the body responds [1]. standard 4 mg The 4 mg dose gave the strongest nerve-fiber regrowth and pain relief in the trial — better than the higher 8 mg dose [1][2]. advanced 8 mg Highest daily dose studied in the sarcoidosis trial. It was safe but did not beat 4 mg for nerve outcomes [1]. 2 mg Three times weekly 4 weeks An earlier sarcoidosis pilot gave 2 mg into a vein three times a week and saw improved nerve symptoms [6]. 250 mcg 1-2 weeks A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2]. 250-500 mcg Twice daily Commonly used range for tissue and tendon recovery in research practice [1][3]. 500 mcg 6-8 weeks Upper end used in practice for more demanding acute injuries [1][3]. Applications Treating small fiber neuropathy ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Managing neuropathic pain from diabetes or sarcoidosis ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Supporting nerve regeneration after injury ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Reducing chronic inflammation ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Tendon and ligament injuries Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair Gut healing IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue Muscle injuries Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression Joint problems Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties Post-surgical recovery Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms Safety Profile Common Injection Site Reactions Headache Dizziness Uncommon Elevated Blood Pressure Fatigue Serious Blood Clot Formation Injection site redness Mild nausea Hot/cold sensations Allergic reaction Research Status FDA Status Not FDA approved Safety Overview ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development. Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns. However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist. Contraindications xPolycythemia vera or erythrocytosis xUncontrolled hypertension xPregnancy or breastfeeding xKnown hypersensitivity to peptides xConcurrent use with certain cancer medications Research compound BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions. xPregnancy xBreastfeeding xActive cancer xHistory of cancer Decision Guide Choose ARA-290 (Cibinetide) if... Treating small fiber neuropathy Managing neuropathic pain from diabetes or sarcoidosis Supporting nerve regeneration after injury Reducing chronic inflammation Choose BPC-157 if... Injury recovery Post-surgery healing Chronic pain management Gut health